To define the clinical phenotype of carriers of genetic mutations associated with impaired PAM-amidating activity (PAM-AMA) and its significance in sarcopenic diabetes.
Key Findings:
Two LoF variants in the PAM gene (Ser539Trp and Asp563Gly) significantly decreased PAM-AMA, with specific statistical values provided.
The cumulative effect of LoF variants was linked to diabetes, reduced insulin secretion, and increased GH and IGF-1 levels.
Carriers exhibited reduced muscle mass and function, with a 30% increased risk of sarcopenia associated with the Ser539Trp mutation, supported by statistical data.
Interpretation:
PAM-AMA genetic deficiency leads to a prediabetic sarcopenic phenotype, suggesting that early identification of PAM LoF carriers could enable targeted interventions to prevent diabetes and sarcopenia.
Limitations:
The study's findings are based on observational data, which may limit causal inferences, and potential confounding factors in cohort studies may affect the outcomes.
Conclusion:
PAM deficiency is implicated in the development of sarcopenic diabetes mellitus, highlighting the need for novel therapies to restore enzymatic activity and improve patient outcomes.
by Alice Giontella, Mikael Åkerlund, Kevin Bronton, Cristiano Fava, Luca A Lotta, Aris Baras, John D Overton, Marcus Jones, Andreas Bergmann, Paul Kaufmann, Yulia Ilina, Olle Melander
